Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
about
Mode of administration of dulaglutide: implications for treatment adherenceEfficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center.Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysisSafety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.Discontinued drug therapies to treat diabetes in 2015.Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
P2860
Q26744065-FE6B23BA-3E59-49AE-928B-68B726918644Q30240808-45615F57-9246-4F0B-A647-1D6EE35E590EQ30249371-78C7BEBA-D797-4BAE-AA48-39DE7FB4A6CAQ33775785-C60B77A8-5781-4BCF-BE04-A0D5E0BFE97AQ36285880-4D4DD6CC-6DC6-4A27-9D20-A9F34D815559Q36354602-20B1918D-EAB7-41ED-84CE-A233DDE81B6BQ37661798-976E4395-3777-4168-B06B-6DF138B74CA9Q38908205-3147021D-B02B-4A32-817D-BAEF5A16B1FFQ38975192-17BF7D65-F410-4A36-A06D-9345367E617FQ39031158-9727DC1A-0FA6-4E95-994B-8F5127754775Q47172049-8B5A5BB5-2540-4005-988A-1C42EAB701E8Q47769217-1D778DF3-5C51-40E3-8BCA-8AEBEC043EEEQ51278208-8E701978-A248-4D8D-81EF-9AE1D805D0A6Q51327624-B7776AFD-940B-4B06-BFD6-2FA6A68B82E6Q55401199-0FD7A81E-78F5-43F5-94A7-366992BE943F
P2860
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and safety of once-we ...... randomized controlled trials.
@ast
Efficacy and safety of once-we ...... randomized controlled trials.
@en
type
label
Efficacy and safety of once-we ...... randomized controlled trials.
@ast
Efficacy and safety of once-we ...... randomized controlled trials.
@en
prefLabel
Efficacy and safety of once-we ...... randomized controlled trials.
@ast
Efficacy and safety of once-we ...... randomized controlled trials.
@en
P2093
P2860
P50
P356
P1476
Efficacy and safety of once-we ...... randomized controlled trials.
@en
P2093
D R Matthews
D Vasilakou
E Athanasiadou
P2860
P304
P356
10.1111/DOM.12541
P577
2015-07-15T00:00:00Z